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Abstract
Background: In clinical practice the gold standard method to assess BRAF status in patients with metastatic
melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects
the BRAF V600E mutated protein, has been developed. With this study we aimed to confirm the clinical value of
the VE1 Ventana® antibody, as today a univocal validated and accredited immunohistochemical procedure does not
exist, to preliminary detect BRAF status in our routine diagnostic procedures. Moreover, we explored the biological
meaning of BRAF immunohistochemical labeling both as a predictor marker of response to target therapy and, for
the first time, as a player of acquired tumor drug resistance.
Methods: We analyzed a retrospective series of 64 metastatic melanoma samples, previously investigated for
molecular BRAF status, using a fully automatized immunohistochemical method. We correlated the data to the
clinicopathologic characteristics of patients and their clinical outcome.
Results: The sensitivity and the specificity of the Ventana® VE1 antibody were 89.2 and 96.2% respectively, while
the positive predictive value and negative predictive value were 97.1 and 86.2%, respectively. For six mutated
patients the histological sample before treatment and when disease progressed was available. The immunohistochemical
BRAF V600E expression in the specimens when disease progressed was less intense and more heterogeneous compared
to the basal expression. Multivariate analysis revealed that a less intense grade of positive expression is an independent
predictor of a less aggressive stage at diagnosis (p = 0.0413).
Conclusions: Our findings encourage the introduction of immunohistochemistry as a rapid screening tool for the
assessment of BRAF status in melanoma patients in routine diagnostic procedures and prepare the ground for other
studies to highlight the role of immunohistochemical BRAF V600E expression in patients at the time of progression.
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Background
Melanoma is a challenging malignancy to treat, and with
its increasing incidence is the fifth and the seventh most
common cancer diagnosed in men and women respect-
ively [1]. About 40–60% of cutaneous melanomas have
BRAF mutations and 90% of these involve a specific mis-
sense substitution of valine by glutamic acid at codon
600 (V600E). This mutation constitutively activates the
protein and the downstream MAPK signaling pathway
in a RAS-independent manner, promoting proliferation,
survival and spreading of tumor cells [2]. Metastatic
melanoma patients harboring this hot spot mutation can
be effectively treated with BRAF inhibitors alone or in
combination with MEK inhibitors [3, 4] because this
genetic alteration is predictive to therapeutic response.
Therefore, rapid screening for BRAF status in patients
with unresectable or metastatic melanoma has recently
become integral to treatment decisions and essential for
optimal patient care. In clinical practice the gold
* Correspondence: a.mangia@oncologico.bari.it
†Equal contributors
1Functional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni
Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schirosi et al. BMC Cancer  (2016) 16:905 
DOI 10.1186/s12885-016-2951-4
standard and the most commonly used method to assess
BRAF status is based on DNA molecular assays. The
most common ones are the classical Sanger sequencing,
pyrosequencing and the FDA-approved cobas® 4800
BRAF V600 mutation test. Each method has its own
sensitivity, specificity, cost and response delay [5, 6].
However, the molecular methods are often more time
consuming and not always routinely available in all ana-
tomic pathology laboratories. Moreover, some diagnostic
samples are still unsuitable for molecular testing because
of their inadequate tumor content and the variable qual-
ity of DNA extracted due to fragmentation that occurs
with tissue processing. The effect of melanin pigment on
molecular assays is also important. Thus, there are cir-
cumstances when the alternative diagnostic BRAF muta-
tion detection method may have utility [7]. Recently, a
mutation-specific mouse monoclonal antibody (clone
VE1), which does not detect other mutant BRAF V600
epitopes or the wild type form but only the BRAF
V600E mutated protein, has been developed [8] and it is
now commercially available from Spring Bioscience and
Ventana®. It has been previously shown that immunohis-
tochemistry (IHC) with this antibody is sensitive and
specific for the detection of the genomic BRAF V600E
mutation [9–11]. This finding has permitted the use of
IHC, which is a potentially faster, less expensive, and
more available methodology to assess BRAF status in
the formalin-fixed and paraffin-embedded tissue of mel-
anoma patients [2].
The aim of our study was to confirm the clinical value
of the VE1 Ventana® antibody as we plan to use an immu-
nohistochemical method to preliminary detect BRAF sta-
tus in our routine diagnostic procedures. We intend to
use a fully automatized immunohistochemical method,
marked CE-IVD, to analyze a retrospective series of meta-
static melanoma samples previously investigated for BRAF
genetic status by molecular techniques and to compare
the results obtained by the two methods, as today a uni-
vocal validated and accredited immunohistochemical pro-
cedure and criteria for analysis does not exist.
Moreover, we propose to explore the biological mean-
ing of BRAF immunohistochemical labeling both as a
marker predictive of response to target therapy and as a
player of acquired tumor drug resistance. Therefore, we
intend to correlate the data to the clinicopathologic
characteristics of patients and their clinical outcome,
and to compare, in a small subset of patients, BRAF la-
beling before treatment and when disease progressed.
Methods
Patients and samples
Our retrospective study included 64 patients enrolled
from June 2008 to April 2015 with histologically con-
firmed metastatic melanoma treated at the IRCCS
Istituto Tumori “Giovanni Paolo II” of Bari, with a me-
dian age at diagnosis of 61 years (range 22–82 years); 35
patients were male (54.7%) while 29 were female
(45.3%). Clinical and follow-up data were collected and
evaluated in the entire set of patients, according to
approval by the local Ethics Committee of the IRCCS
Istituto Tumori “Giovanni Paolo II” of Bari (prot. no.
515/EC of May 12, 2015). All patients signed informed
consent form authorizing the Institute to utilize bio-
logical materials for research purpose according to eth-
ical standards. The study was conducted in accordance
with the international standards of good clinical practice.
The immunohistochemical analysis of BRAF status was
conducted after the end of treatment and, thus, did not
influence any therapeutic choice. Regarding the tested
samples, five were primary melanoma while the others
were principally subcutaneous metastasis (25/64 cases)
and lymph node metastasis (21/64 cases), followed by
metastasis in other anatomical sites such as the gut,
brain, liver (n = 13). In all cases the assessment of BRAF
status had been previously performed by some molecular
techniques introduced over the years in the genetic la-
boratory: for 29 cases the cobas® BRAF V600 test was
used, in 22 cases Sanger sequencing was applied, and for
the other samples pyrosequencing (13 cases). Forty-two
cases were BRAF mutated at codon 600 (V600E in 37
patients and V600K in five patients), whereas 22 patients
were BRAF wild type. The clinicopathological character-
istics of the overall cohort and BRAF inhibitor treated
patients are shown in Table 1. The site of primary mel-
anoma was the skin in 54 patients, unknown in eight
and uveal in two cases. Only one case had stage I disease
at diagnosis, 19 (30.1%) patients were at stage II, 26
(41.3%) were at stage III and 17 (27%) at stage IV. Ac-
cording to the American Joint Committee on Cancer
(AJCC) melanoma staging system, 13 patients (20.3%)
had M1a disease, nine patients (14.1%) had M1b disease
and 42 (65.6%) had M1c stage. Twenty-three patients
(35.9%) had brain metastasis and 36 (56.3%) had more
than two metastatic sites. We also considered Disease
Free Survival (DFS), as the time (in months) from diag-
nosis to the date of the first metastasis and the median
was of 12 months (range 0–144). Overall Survival (OS)
was defined as the time (in months) from diagnosis to
the date of last contact or of death from any cause and
the median OS resulted of 32 months (range 2–182),
while the median value of OS from metastatic disease
(OSMD) to the date of last contact or of death from
any cause was 12.5 months (range 2–86).
Among the BRAF mutated patients, nine were never
treated: in seven cases because of a sudden fall in per-
formance status which led to death and in two cases due
to a metastasectomy which left them without evidence
of disease. The remaining 33 (51.6%) patients of this
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metastatic melanoma population were treated with
BRAF inhibitors. Eighteen patients were treated as first
line therapy, 10 as second line and five as third line.
Twenty-six patients (78.8%) were treated with Vemurafe-
nib, and seven patients (21.2%) with Dabrafenib at the
standard dose of 960 mg and 150 mg respectively twice
daily until progression. In this subset of patients we
compared also BRAF inhibitor treatment outcome to the
immunohistochemical staining. Patients were selected if
they had measurable lesions; adequate renal, hepatic and
bone marrow functions; an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤ 2; a life expect-
ancy of more than 12 weeks; and did not need dose
reduction or withholdings of doses of BRAF inhibitors
for related toxicities.
Patients underwent clinical and laboratory exams
every 4 weeks and radiological evaluation with tumor as-
sessments at baseline and then approximately every
12 weeks in order to evaluate therapeutic effectiveness.
Response Evaluation Criteria In Solid Tumors (RECIST)
version 1.1 was used for efficacy assessment [12]. We
assessed the best response during BRAF inhibitors as
complete response (CR), partial response (PR), stable
disease lasting for at least 12 weeks (SD) and progressive
disease (PD). We also measured Progression Free Sur-
vival (PFS), defined as the length of time from the start
of the treatment until disease progression.
As best response we assessed four CR (12.1%), 22 PR
(66.7%) and seven PD (21.2%). The median value of PFS
was 6 months (range 1–40) and at the time of the final
statistical analysis, conducted in November 2015, all
patients had progressed after BRAF inhibitor treatment.
For six of these patients the sample at the time of
progression was also available and BRAF immunohisto-
chemical analysis was performed also in these speci-
mens to compare the level of expression compared to
the basal one.
Immunohistochemistry
IHC was performed on the same formalin-fixed,
paraffin-embedded tissue block used for mutational test-
ing and the histological sections of the relative samples
were reviewed by a pathologist to assure the presence of
a sufficient tumor content. All specimens were cut into
3–4 μm-thick slices to make sections for immunohisto-
chemical staining using a fully automatized assay based
on the Ventana® BRAF V600E (VE1) mouse monoclonal
primary antibody on the Ventana® Benchmarck XT
(Ventana-Roche Diagnostics, Meylan, France) automated
slide strainer in combination with the Ventana OptiView
DAB IHC Detection Kit®. Briefly, according to the manu-
facturer’s procedure, after deparaffinization using the EZ
Prep® reagent, the slides were pretreated with Cell Con-
ditioning 1® for 64 min for antigen unmasking and
followed by pre-primary antibody peroxidase inhibition.
The slides were then incubated with the VE1 antibody at
37 °C for 16 min, and counterstained with Hematoxylin
II® for 4 min and Bluing Reagent® for 4 min. Subse-
quently slides were removed from the immunostainer,
washed in water with a drop of dishwashing detergent
and mounted. Negative (a sample wild type for BRAF
V600E) and positive (a sample with the known V600E
mutation) controls were included in each round of ana-
lysis. No chromogen was detected when the primary
Table 1 Clinicopathological characteristics of overall and BRAF
inhibitor treated patients
Characteristics Overall BRAF inhibitor treated
N (%) N (%)
Patients 64 (100) 33 (100)
Sex
Male 35 (54.7) 17 (51.5)
Female 29 (45.3) 16 (48.5)
Age
Median (range) 61 (22–82) ─ 53 (22–82) ─
Site of primary melanoma
Skin 54 (84.4) 29 (87.9)
Unknown 8 (12.5) 4 (12.1)
Uveal 2 (3.1) 0 (0)
Stage at diagnosis
I 1 (1.6) 1 (3.1)
II 19 (30.1) 8 (24.2)
III 26 (41.3) 14 (42.4)
IV 17 (27) 10 (30.3)
Metastatic stage
M1a 13 (20.3) 7 (21.2)
M1b 9 (14.1) 6 (18.2)
M1c 42 (65.6) 20 (60.6)
Brain metastasis
No 41 (64.1) 23 (69.7)
Yes 23 (35.9) 10 (30.3)
N° metastasis
≤ 2 28 (43.7) 13 (39.4)
> 2 36 (56.3) 20 (60.6)
DFS
Median (range) 12 (0–144) ─ 12 (0–136) ─
OS
Median (range) 32 (2–182) ─ 31.5 (5–145) ─
OSMD
Median (range) 12.5 (2–86) ─ 14 (4–54) ─
DFS disease free survival, OS overall survival, OSMD overall survival from
metastatic disease
For one patient the stage at diagnosis was unknown
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antibody was omitted. All immunoreactive samples were
scored by double-blinded independent observers who
had no information on patient clinical and molecular
data. The results from the two observers were identical
in most cases, and the few discrepancies were resolved
by re-examination and consensus. The VE1 antibody
shows a cytoplasmic staining in positive tumor cells. Im-
munostaining was primarily interpreted as positive or
negative according to Boursault et al. [13]. The slides
were scored as positive when more than 90% of tumor
cells showed a clear moderate to strong brown cytoplas-
mic staining, while they were considered negative when
there was no staining or only nuclear dot staining, weak
staining of single interspersed cells, or staining of
monocytes/macrophages. Secondly the intensity of im-
munostaining was graded 0 if there was no visible
staining, grade 1 if weak diffuse cytoplasmic back-
ground staining was present, grade 2 if moderate dif-
fuse and granular cytoplasmic staining was observed
and grade 3 if strong mainly granular cytoplasmic stain-
ing was detected. No staining (grade 0) and staining
grade 1 were regarded as negative for V600E, while
grade 2 and grade 3 were regarded as positive samples
according to Løes et al. [14].
Statistical analyses
The sensitivity of Ventana® VE1 immunostaining was
measured as the proportion of the immunohistochemical
positive cases in the molecular assay positive cases, while
the specificity was determined as the proportion of the
immunohistochemical negative cases in the molecular
assay negative cases. Positive predictive value and nega-
tive predictive value of the VE1 antibody as compared to
molecular analysis were also calculated. Concordance
between immunohistochemical expression and molecu-
lar analysis was performed using GraphPad QuickCalcs
software. A kappa coefficient (k) value of 0.41 to 0.6 in-
dicates moderate agreement, 0.61 to 0.8 substantial
agreement and more than 0.8 almost perfect agreement
(95% confidential intervals).
Comparison of clinicopathological parameters be-
tween the groups of interest (IHC positive and negative,
IHC grade 2 and grade 3, mutated and non mutated by
molecular techniques, mutated patients treated with
BRAF inhibitors and mutated patients non treated)
were performed with the Mann Whitney test and the
Pearson χ2 test or Fisher’s Exact test, when appropriate,
for continuous and categorical variables, respectively.
The multivariate logistic regression model was used to
investigate the effect of some confounding factors on
the relation between the outcomes of interest and all
the parameters presenting significant association at the
univariate analysis.
Survival statistics (DFS, OS, OSMD, PFS) were esti-
mated with the Kaplan-Meier method and the differ-
ences between groups of interest was validated by the
Log-rank test. The multivariate Cox regression model
was used to test for the effect of BRAF status after
adjusting for known confounders.
A p value < 0.05 was considered significant. All the
statistical analyses were performed using SPSS version
17.0 software (SPSS, Inc., Chicago, IL, USA).
Results
All 64 collected melanoma samples contained a sufficient
tumor content to perform immunohistochemical analysis.
The Ventana® immunohistochemical assay, using the VE1
mouse monoclonal primary antibody, showed an inter-
pretable result in 63/64 (98.4%) cases. Only one case was
not evaluable. It was a subcutaneous metastasis with large,
polygonal melanoma cells with very high amount of mel-
anin pigment in cytoplasm and in the surrounding stroma
that resulted in nonspecific immunohistochemical re-
activity. The samples with the BRAF V600E mutation re-
sulted positive in the cytoplasm to VE1 immunostaining,
whereas the cases with only the BRAF V600K mutation
and with the double BRAF V600K and BRAF V600G mu-
tation remained completely immunonegative. The 34/63
(54%) cases were scored as positive in IHC and showed a
moderate to strong brown cytoplasmic staining in more
than 90% of tumor cells. In particular, 18 cases resulted
grade 2 (Fig. 1a) while the others (n = 16) grade 3 (Fig. 1b).
The immunoreactivity was almost homogeneous through-
out tumor areas and cells, while differences in staining in-
tensity in the analyzed sections were observed in very few
cases. The 33/34 (97.1%) immunopositive cases also re-
sulted BRAF V600E mutated, confirming what molecular
analysis had found. The 29/63 (46%) cases were evaluated
as negative: 18 cases were scored as grade 0 (Fig. 1c) while
11 as grade 1 (Fig. 1d). In detail, considering both IHC
and molecular techniques 58/63 cases (92.1%) showed
concordant results, except five cases (7.9%) which were
discrepant even after a second repeated immunohisto-
chemical test. In detail, one case was immunopositive
(grade 3) but negative by Sanger sequencing analysis
(Fig. 2), while the remaining four cases, which were scored
as negative (3 cases were grade 1 and one case was grade
0) in IHC, were BRAF V600E mutated when analyzed by
Sanger sequencing (2 cases) and the cobas® BRAF V600
test (2 case). Thus, compared to molecular analyses, the
sensitivity and the specificity of the Ventana® VE1 anti-
body were 89.2 and 96.2% respectively, while the positive
predictive value and negative predictive value were 97.1
and 86.2%, respectively. Moreover, correlation analysis
was performed between immunohistochemical expression
and molecular data and resulted in a very good match,
since the agreement was 92.1% and k was 0.839. In
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Fig. 2 Immunohistochemical and molecular BRAF status in a discordant melanoma case. a Immunohistochemical BRAF V600E expression graded
as three near to an area enriched by lymphocytic normal cells (original magnification: ×20). b Sense and c antisense sequence of a region of
BRAF exon 15 in which the V600 codon wild type is underlined
Fig. 1 Grade of immunoreactivity of the BRAF V600E Ventana® VE1 antibody in melanoma samples. a Moderate diffuse and granular cytoplasmic
staining graded as 2. b Strong granular cytoplasmic staining graded as 3. c Negative staining graded as 0. d Weak diffuse cytoplasmic
background staining graded as 1. (Original magnification: ×20)
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relation to each single molecular technique, as reported in
Table 2, IHC showed a perfect agreement (100%) only
with pyrosequencing (k = 1), while the concordance was
good (93.1%) with the cobas® BRAF V600 test (k = 0.760)
and with Sanger sequencing (85.7%; k = 0.632).
Considering all patients we correlated the immunohis-
tochemical results (negative versus positive samples), the
IHC-positive cases (grade 2 versus grade 3), molecular
results (mutated versus non mutated patients) and the
BRAF-mutated inhibitor treated versus the mutated non
treated patients with the following clinicopathologic
characteristics: sex, age, stage at diagnosis, metastatic
stage of disease, brain metastasis and number of metas-
tasis. We found a statistically significant correlation be-
tween the IHC results and sex (p = 0.0479) and age (p =
0.001) as reported in Table 3. Age was also significantly
correlated with molecular results (p = 0.0253). The non
mutated patients had a median age of 63.64 years while
the mutated ones of 53.61 years (data not shown).
Kaplan-Meier curves respect to DFS, OS, OSMD
showed no statistically significant results. Multivariate
analysis, including all the clinicopathologic characteris-
tics as confounding factors, identified grade 2 immuno-
reactivity as an independent predictor for stage I or II at
diagnosis (p = 0.0413; Odds Ratio = 11.520; Confidence
Interval 1.102 -120.432).
We also considered the subset of patients treated with
BRAF inhibitors (n = 33), and correlated the negative
versus positive IHC results and the IHC-positive samples
(grade 2 versus grade 3) with sex, age, stage at diagnosis,
metastatic stage of disease, brain metastasis, number of
metastases and the best response during BRAF inhibi-
tors. Only age resulted in significant association with
IHC results, confirming what had been found in all pa-
tients (p = 0.0367). Kaplan-Meier curves respect to PFS
and multivariate analysis showed no statistically signifi-
cant results.
With regard to the best BRAF inhibitor response for
the discordant cases (n = 5), one patient was BRAF
V600E by IHC, but he did not receive treatment with
BRAF inhibitors on the basis of the wild type molecular
result. The OSMD of this patients was of 2 months re-
spect to the median of 12.5 months. Regarding the four
cases negative by IHC but mutated by molecular
analysis, one patient showed PR, another CR and the last
two patients had not been treated.
Moreover, for six BRAF V600E mutated and treated
patients the histological sample before treatment and
when disease progressed was available. We analysed im-
munohistochemical BRAF V600E expression also in
these last samples in order to compare the BRAF stain-
ing between the pre- and post-treatment specimens. For
each patient we noted a difference in BRAF V600E ex-
pression between the two samples. In detail, in the speci-
mens when disease progressed we observed a more
heterogeneous BRAF V600E staining and areas of neo-
plastic cells characterized by an intensity of expression
weaker than the basal samples, as reported in Fig. 3.
However, we not noted any difference among these six
patients comparing the post-treatment BRAF V600E
staining to their treatment response and PFS.
Table 2 Correlation between immunohistochemical analysis and molecular methods
Sanger sequencing Cobas® test Pyrosequencing
positive negative positive negative positive negative
IHC positive 4 1 23 0 6 0
negative 2 14 2 4 0 7
Total 6 15 25 4 6 7
Concordance 85.7% (k = 0.632) 93.1% (k = 0.760) 100% (k = 1)
IHC immunohistochemistry
Table 3 Correlation of BRAF IHC results and clinicopathological
characteristics
BRAF IHC
Characteristics NEGATIVE (N = 29) POSITIVE (N = 34) p value
Sex
Male 20 (68.97) 15 (44.12) 0.0479*
Female 9 (31.03) 19 (55.88)
Age
64.55 ± 12.94 51.18 ± 15.33 0.001*
Stage at diagnosis
I + II 7 (24.14) 12 (36.36) 0.2975
III + IV 22 (75.86) 21 (63.64)
Metastatic stage
M1a 8 (27.59) 5 (14.71) 0.0564
M1b 1 (3.45) 8 (23.53)
M1c 20 (68.97) 21 (61.76)
Brain metastasis
No 20 (68.97) 21 (61.76) 0.5501
Yes 9 (31.03) 13 (38.24)
N° metastasis
≤ 2 13 (44.83) 15 (44.12) 0.9549
> 2 16 (55.17) 19 (55.88)
*p < 0.005
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Discussion
Immunohistochemistry already covers a central role in
the diagnostic pathological setting. In the era of person-
alized medicine its importance and utility are increasing,
since it is a relatively rapid and cheap technique that
does not require huge tumor cell content [15]. It is also
easy to execute and is considered highly sensitive and
specific because the antibodies used, and particularly
the mutation-specific monoclonal antibodies, are typic-
ally directed against the antigen of therapeutic interest
[7, 16]. In this scenario, a new recent monoclonal anti-
body named VE1 has been developed [8], directed
against the mutant BRAF V600E protein, which is the
actual target of BRAF inhibitors employed in clinical
practice [17].
In our set only one sample resulted not evaluable by
immunohistochemical analysis because of the presence
of so much melanin that the case was uninterpretable.
The Ventana OptiView DAB IHC Detection Kit® is a fully
automated high-throughput kit that uses 3,3' diamino-
benzidine (DAB) as a chromogen of brown intensity.
When samples contain an excess of brown tissue pig-
ments, such as melanin, the immunostaining obtained
using this kit should be evaluated with caution as it could
be a source of interpretative errors [18]. To mitigate for
this potential pitfall it is preferable to use a red chromo-
gen, as was carried out in some studies [5, 11, 19–21]. In
particular, Thiel et al. [20] referred that melanoma speci-
mens without or with a low content of pigment were eas-
ily scored using the DAB chromogen, but in cases with
extensive pigmentation successful scoring was obtained
using fast Red chromogen. In the near future we are also
evaluating the possibility to use another chromogen kit for
these particular cases. If this is not available routinely, it is
necessary to opt for a different BRAF status detection
technique.
The sensitivity and specificity of the Ventana® VE1
antibody found in our study are in line with previous
reports that showed them to be in the range of 85 to
100% and 93 to 100% respectively, but these reports
used principally the antibody distributed by Spring Bio-
science [5, 6, 9, 11, 19, 22]. In particular, considering
the study of Qiu et al. [23], who instead used the same
fully automatized immunohistochemical method as we
did, they found that the sensitivity and specificity of the
VE1 antibody were 100 and 99%, respectively. However,
it is to consider that in their set there were only 41
cases of malignant melanoma while the majority of
them were colorectal carcinomas (611 samples) and
papillary thyroid carcinomas (127 specimens) [23]. Our
results are close to those of Yaman et al. [24], who, in a
study on 48 cases with both primary cutaneous and
metastatic melanoma using the fully automatized Ven-
tana® immunohistochemical method with the addition
Fig. 3 Representative images of BRAF V600E immunohistochemical expression in two patients before treatment and in progression. a, c In the
specimens before treatment we observed a homogeneous BRAF V600E grade 3 immunohistochemical expression. b, d In the samples when
disease progressed we observed a less intense and more heterogeneous BRAF V600E staining. (Original magnification: ×20)
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of an amplification signaling kit, reached a positive pre-
dictive value of 98.2% and a negative predictive value of
89.7%. More recently Long et al. [25] conducted a study
considering 188 metastatic melanoma patients to com-
pare the sensitivity and specificity of the same fully au-
tomatized Ventana® immunohistochemical method
respect to the pyrosequencing analysis. They obtained a
100% sensitivity and specificity but they considered that
the VE1 antibody was positive for BRAF V600E only
when strong immunostaining (3+) was observed in at
least 80% of tumor cells [25]. Even in our cohort, all
grade 3 cases were mutated by molecular analyses, ex-
cept for the only discordant molecular BRAF wild type,
but even all grade 2 cases also resulted BRAF V600E
mutated and in addition three cases graded as 1 and
one case graded as 0. In our experience, as supported
by other studies [10, 18, 24], also grade 2 staining was
associated with mutational BRAF V600E status, even if
we considered positive the cases with more than 90% of
immunoreactive cells. Thus our combination of scoring
criteria could be considered valid for immunohisto-
chemical BRAF analysis. Moreover, some false negative
results may occur in the case of a long period of cold
ischemia and of hypo- or hyper-fixation with formal-
dehyde [25]. Therefore, in agreement with Long et al.
[25], we encourage each laboratory to set the pre-
analytical and analytical parameters and to define, by a
comparative immunohistochemical-molecular study,
the cut-off values in the evaluation of BRAF immuno-
staining, as today an univocal, validated and accredited
immunohistochemical procedure and scoring system
for BRAF status does not exist. Our results could there-
fore be considered useful in this scenario and encour-
aging to reach this purpose.
Moreover, the concordance reached in our study be-
tween immunohistochemical expression and molecular
data showed a very good match and an almost perfect
agreement, even if five discordant cases were recorded.
In particular, one case resulted immunopositive but wild
type using Sanger Sequencing. This was also reported by
Thiel et al. [20], highlighting the importance of perform-
ing immunohistochemical staining before DNA extrac-
tion for mutational analysis, especially when Sanger
Sequencing is used. This molecular technique, in fact,
has the lowest sensitivity of the molecular techniques,
finding only 20% mutated alleles in a background of wild
type alleles [26]. The discrepancy thus could be attrib-
uted to the low mutational rate in the DNA extracted or
because of intratumoral heterogeneity regarding the
presence of BRAF mutated protein [27]. In other studies
[9, 24, 28] cases where IHC was positive while a negative
result was obtained with a molecular method were also
reported, but in some instances the presence of the
BRAF V600E mutation has been demonstrated with
secondary more sensitive molecular techniques. In our
case, in the immunohistochemical section we observed
the presence of a significant number of normal lympho-
cytes near the relatively low number of neoplastic cells
and there was a very small fraction of non-reactive neo-
plastic cells. Unfortunately a second DNA extraction in
a microdissected area could not be performed and the
molecular analysis with other more sensitive methods on
the previous extract could not be repeated due to the
lack of residual material. The fact that not all mutated
BRAF V600E samples are IHC-positive, as verified in
our other discordant cases, supports the use of DNA
mutational analysis only in negative or uncertain pa-
tients as they could be a possible immunohistochemical
false negative, harboring either a BRAF V600E mutation
or another BRAF mutational variant [21]. In fact, one
disadvantage of the use of this antibody in the diagnostic
setting is that it is necessary to use an alternative
method to detect the other BRAF V600 mutations, in-
cluding in particular BRAF V600K. This genetic alter-
ation is the second most common mutation, and it is
responsive to dabrafenib, the second BRAF inhibitor
currently used in clinical practice [5]. Similar to the ma-
jority of other studies [5, 9, 19, 20, 24] we did not detect
any cross-reactivity of the VE1 antibody with the BRAF
V600K mutated protein, present in five cases. Finally, in
our findings IHC showed a perfect agreement with pyro-
sequencing and a good concordance with the cobas®
BRAF V600 test. Pyrosequencing and cobas® are two of
the most sensitive molecular methods, able to identify
2% and ≥5% respectively of BRAF V600E mutated alleles
in a background of wild type alleles [6]. In support of
this finding, Colomba et al. [5] proved that pyrosequenc-
ing is the most efficient method to detect BRAF
mutations in melanomas and it should be performed
only on VE1-negative or uninterpretable cases. Cobas®
test, moreover, is a mutation assay designed to detect
BRAF V600E mutation, but it is reported also cross-
reactivity with BRAF V600K [6, 18]. Thus, in our study,
the two cases that resulted mutated by cobas® test and
negative by IHC could have a mutation different from
V600E. Unfortunately this has not been verified by other
molecular methods because of the lack of residual mater-
ial. Our results, supported by the evidence of the literature
[5, 11, 19, 24, 25], suggest the use of an algorithm in the
melanoma BRAF diagnostic setting (Fig. 4). In this model,
IHC should be used in the first instance as a screening
tool. The cases resulting VE1 immunonegative should be
secondly tested by a DNA mutational assay, using in par-
ticular the more sensitive ones to rule out possible false
negative samples or those with different BRAF mutations.
When comparing the cost-effectiveness of IHC and mo-
lecular methods there was a strong difference of about
250,00 € between the two assays. Similarly there was a
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strong difference between the turnaround time, in fact an
IHC result was obtained in 24 h whereas the molecular re-
sults need of about at least 4–5 days’ work. Thus, this
practical algorithm represents the best way in terms of ad-
equacy, rapidity and cost-effectiveness to screen melan-
oma patients for BRAF V600E mutation.
Regarding the correlation between clinicopathologic
characteristics and IHC results, age resulted significantly
correlated with BRAF V600E expression. Our finding is
in line with literature that reports that the BRAF
mutation was associated with a younger age of patients
[29, 30]. Moreover, the lack of correlation we found with
DFS and OS further underlines how the BRAF mutation
represents a weak prognostic factor [30]. Considering
the subset of treated patients, we also found that the
level of expression of BRAF V600E did not predict re-
sponse or outcome to BRAF inhibitor therapy in meta-
static melanoma patients, and these results confirmed
what Wilmott et al. [10] had previously found.
This is the first time that IHC has been employed to
evaluate BRAF V600E expression in pre- and post-
treatment specimens. Despite the restricted number of
examined cases, we could suppose that there is a mech-
anism of resistance which could be linked to the de-
crease of the level of BRAF V600E expression also
accompanied by the heterogeneity of its expression. It
could be explained if progression occurs or when resist-
ant tumor subclones expand under the selective pressure
of BRAF inhibitors, or as a result of an evolutionary
process during treatment, or a combination of both [31].
Considering that in six analyzed cases, regardless the
kind of response obtained and the PFS achieved by
patients, we found the same pattern of BRAF staining at
progression, this biological mechanism of BRAF inhibi-
tor resistance could be relatively common. Thus the ana-
lysis of this aspect during the disease progression of
mutated patients could be useful in clinical setting man-
agement and could support the effort of a combination
between BRAF inhibitors and chemotherapy [32]. In our
study, we found that a less intense grade of positive ex-
pression is an independent predictor of a less aggressive
stage at diagnosis. We hypothesize that the intensity of
BRAF V600E expression could be correlated to tumor
stage aggressiveness at diagnosis in melanoma patients.
Conclusions
In conclusion, these findings should be confirmed by
other studies which could highlight the role of IHC to
detect BRAF V600E expression in patients at the time of
progression, and to better clarify the meaning of the in-
tensity of positive immunohistochemical expression in
melanoma patients. However, on the basis of our experi-
ence, we encourage the introduction of IHC as a rapid
screening tool for the assessment of BRAF status in mel-
anoma patients in routine diagnostic procedures.
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